Scott Lassman is a partner in Goodwin’s Technology & Life Sciences Group. Mr. Lassman’s practice focuses on providing life cycle support to biotechnology, pharmaceutical and medical technology companies at all stages of development. He has extensive experience counseling senior management on navigating the FDA’s complex administrative processes and structure, including its dispute resolution and Citizen Petition processes, and has successfully obtained preliminary and permanent injunctive relief from the FDA in drug and device cases. He routinely provides strategic advice on product approval and lifecycle management issues, including the Hatch-Waxman Act and biosimilars law, and also advises clients on corporate, licensing and intellectual property issues.

Previously a partner at Kleinfeld, Kaplan & Becker, Mr. Lassman joined Goodwin in 2016.